Document Classification

Section Type: RESULTS

Text: The more recent protocol (AML02) produced improved outcomes for patients aged 10 years to 21 years compared with 2 earlier studies (AML91 and AML97), with 3-year rates of event-free survival (EFS), overall survival (OS), and cumulative incidence of refractory leukemia or recurrence (CIR) for this group being similar to those of patients aged birth to 9 years : EFS : 58. 3 % 5. 4 % versus 66. 6 % 4. 9 % (P =. 20) ; OS : 68. 9 % 5. 1 % versus 75. 1 % 4. 5 % (P =. 36) ; and CIR : 21. 9 % 4. 4 % versus 25. 3 % 4. 2 % (P =. 59).